



Announcement Summary

---

**Entity name**

TELIX PHARMACEUTICALS LIMITED

**Date of this announcement**

Thursday April 23, 2026

**The +securities the subject of this notification are:**

Other

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
New class - code to be confirmed	Convertible Notes (due 22 April 2031)	3,000	22/04/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ACN

**Registration number**

616620369

**1.3 ASX issuer code**

TLX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

23/4/2026



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

Other

**Please specify**

Securities issued as part of a transaction announced on 15 April 2026 in an Appendix 3B.

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

does not have an existing ASX security code ("new class")



## Part 3C - number and type of +securities the subject of this notification (new class)

## New +securities

## ASX +security code

New class - code to be confirmed

## +Security description

Convertible Notes (due 22 April 2031)

## +Security type

+Convertible debt securities

## ISIN code

XS3343227347

## Date the +securities the subject of this notification were issued

22/4/2026

## Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

## Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

Yes

## Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

[ir.telixpharma.com/news-events/news](http://ir.telixpharma.com/news-events/news)

## +Convertible debt securities Details

## Type of +security

Convertible note or bond

## +Security currency

USD - US Dollar

## Face value

USD 200,000.00000000

## Interest rate type

Fixed rate

## Frequency of coupon/interest payments per year

Quarterly

## First interest payment date

22/7/2026

## Interest rate per annum

1.50 %

## Is the interest rate per annum estimated at this time?

No

## s128F of the Income Tax Assessment Act status applicable to the +security

s128F exempt

## Is the +security perpetual (i.e. no maturity)?

No

## Maturity date

22/4/2031

## Select other feature(s) applicable to the +security

Convertible

Redeemable

## Is there a first trigger date on which a right of conversion, redemption, call or put can be exercised (whichever is first)?

Yes

## If yes, what is the first trigger date?

27/5/2026

## Details of the existing class of +security that will be issued if the securities are converted, transformed or



**exchanged**

TLX : ORDINARY FULLY PAID

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Refer to Cleansing Notice dated 20 April 2026 available at [ir.telixpharma.com/news-events/news](http://ir.telixpharma.com/news-events/news).

**Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

The issue of the Convertible Notes was previously announced to the market on 15 April 2026 in an Appendix 3B.

Issue details

---

**Number of +securities**

3,000

**Were the +securities issued for a cash consideration?**

Yes

**In what currency was the cash consideration being paid?**

USD - US Dollar

**What was the issue price per +security?**

USD 200,000.00000000

**Purpose of the issue**

Other

**Additional Details**

Refer to the Company's announcement in relation to the Convertible Notes of 14 April 2026.

---





## Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLX : ORDINARY FULLY PAID	339,113,888

**4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLXAY : DEFERRED SHARE RIGHTS	66,140
TLXAX : DEFERRED SHARE RIGHTS EX-US	60,528
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAZ : SHARE RIGHTS US	384,500
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,289,754
TLXAO : SHARE APPRECIATION RIGHTS	13,417,272
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	175,000
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	9,450
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,275,702
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000
New class - code to be confirmed : Convertible Notes (due 22 April 2031)	3,000



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

US\$600,000,000 worth of Notes, which are convertible (at the Initial Conversion Price of US\$13.8542) into a maximum of 43,308,166 Ordinary Shares in Telix Pharmaceuticals Limited. The Conversion Price is subject to adjustment in accordance with the terms and conditions of the Notes.

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

N/A